0000000000726130

AUTHOR

Donatella Callegari

0000-0002-2574-3826

showing 2 related works from this author

Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Epheephrin system

2015

The Eph receptor-ephrin system is an emerging target for the development of novel anti-angiogenic therapies. Research programs aimed at developing small-molecule antagonists of the Eph receptors are still in their initial stage as available compounds suffer from pharmacological drawbacks, limiting their application in vitro and in vivo. In the present work, we report the design, synthesis and evaluation of structure-activity relationships of a class of Δ(5)-cholenoyl-amino acid conjugates as Eph-ephrin antagonists. As a major achievement of our exploration, we identified N-(3β-hydroxy-Δ(5)-cholen-24-oyl)-L-tryptophan (UniPR1331) as the first small molecule antagonist of the Eph-ephrin syste…

MaleModels MolecularAnti-angiogenic agentsAngiogenesis InhibitorsEpheephrin antagonistsPharmacologyEphA2MiceStructure-Activity RelationshipIn vivoCell Line TumorOral bioavailabilityProteineprotein interaction inhibitorsDrug DiscoveryAnimalsHumansStructure–activity relationshipEphrinAmino AcidsReceptorReceptors Eph Familychemistry.chemical_classificationPharmacologyDose-Response Relationship DrugMolecular StructureAnti-angiogenic agents; Bile acids; EphA2; Epheephrin antagonists; Oral bioavailability; Proteineprotein interaction inhibitors; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryErythropoietin-producing hepatocellular (Eph) receptorEndothelial CellsBiological activityGeneral MedicineEPH receptor A2biological factorsBile acidsAmino acidchemistryBiochemistryEphrins
researchProduct

Comparative analysis of virtual screening approaches in the search for novel EphA2 receptor antagonists

2015

The EphA2 receptor and its ephrin-A1 ligand form a key cell communication system, which has been found overexpressed in many cancer types and involved in tumor growth. Recent medicinal chemistry efforts have identified bile acid derivatives as low micromolar binders of the EphA2 receptor. However, these compounds suffer from poor physicochemical properties, hampering their use in vivo. The identification of compounds able to disrupt the EphA2-ephrin-A1 complex lacking the bile acid scaffold may lead to new pharmacological tools suitable for in vivo studies. To identify the most promising virtual screening (VS) protocol aimed at finding novel EphA2 antagonists, we investigated the ability of…

Cell signalingDatabases Pharmaceuticaldrug designPharmaceutical ScienceComputational biologyBiologyCrystallography X-RayMolecular Docking SimulationArticleAnalytical Chemistrylcsh:QD241-441Structure-Activity RelationshipUser-Computer Interfacelcsh:Organic chemistryPPI inhibitorsDrug Discoveryshape screeningStructure–activity relationshipPhysical and Theoretical ChemistryReceptorProtein Kinase InhibitorsVirtual screeningMolecular StructureDrug discoveryReceptor EphA2EphA2 antagonistOrganic ChemistryEphrin-A1virtual screeningEPH receptor A2C700Combinatorial chemistryMolecular Docking SimulationUniPR129Chemistry (miscellaneous)Docking (molecular)dockingMolecular Medicinepharmacophore search
researchProduct